[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100653104":3},{"organization":4,"outcomesModule":7,"designInfo":26,"detailedDescription":11,"studyPopulation":11,"armGroups":36,"interventions":53,"overallOfficials":62,"centralContacts":66,"locations":11,"responsibleParty":74,"collaborators":11,"id":76,"slug":77,"hasResults":78,"nctId":79,"briefTitle":80,"officialTitle":81,"acronym":82,"eligibilityCriteria":83,"healthyVolunteers":78,"sex":84,"minAge":85,"maxAge":86,"enrollmentInfo":87,"targetDuration":11,"studyType":90,"phases":91,"briefSummary":93,"conditions":94,"keywords":11,"overallStatus":96,"whyStopped":11,"lastUpdateSubmitDate":97,"lastUpdatePostDateStruct":98,"startDateStruct":101,"completionDateStruct":103,"leadSponsor":105,"locationsCount":11},{"fullName":5,"class":6},"Hoffmann-La Roche","INDUSTRY",{"primaryOutcomes":8,"secondaryOutcomes":13,"otherOutcomes":11},[9],{"measure":10,"description":11,"timeFrame":12},"Change From Baseline to Week 72 in Clinical Dementia Rating, Sum of Boxes (CDR-SB)",null,"From baseline up to Week 72",[14,16,18,21,24],{"measure":15,"description":11,"timeFrame":12},"Change From Baseline Through Week 72 in Alzheimer's Disease Assessment Scale-Cognition 13 (ADAS-Cog-13)",{"measure":17,"description":11,"timeFrame":12},"Change From Baseline Through Week 72 in Alzheimer's Disease Cooperative Study - Activities of Daily Living Inventory (ADCS-ADL) Total Score and Instrumental Score",{"measure":19,"description":11,"timeFrame":20},"Incidence of Adverse Events (AEs)","Up to approximately Week 76",{"measure":22,"description":11,"timeFrame":23},"Change From Baseline in Columbia-suicide Severity Rating Scale (C-SSRS)","From baseline up to Week 76",{"measure":25,"description":11,"timeFrame":20},"Plasma Concentrations of RO7568282 and its Metabolite[s]",{"allocation":27,"interventionModel":28,"interventionModelDescription":11,"primaryPurpose":29,"observationalModel":11,"timePerspective":11,"maskingInfo":30},"RANDOMIZED","PARALLEL","TREATMENT",{"masking":31,"maskingDescription":11,"whoMasked":32},"TRIPLE",[33,34,35],"PARTICIPANT","CARE_PROVIDER","INVESTIGATOR",[37,43,47],{"label":38,"type":39,"description":40,"interventionNames":41},"RO7568282 High Dose","EXPERIMENTAL","Participants will receive high dose of RO7568282.",[42],"Drug: RO7568282",{"label":44,"type":39,"description":45,"interventionNames":46},"RO7568282 Low Dose","Participants will receive low dose of RO7568282.",[42],{"label":48,"type":49,"description":50,"interventionNames":51},"Placebo","PLACEBO_COMPARATOR","Participants will receive RO7568282 matching placebo.",[52],"Drug: Placebo",[54,59],{"type":55,"name":56,"description":57,"armGroupLabels":58,"otherNames":11},"DRUG","RO7568282","RO7568282 will be administered as specified in the protocol.",[38,44],{"type":55,"name":48,"description":60,"armGroupLabels":61,"otherNames":11},"RO7568282 matching placebo will be administered as specified in the protocol.",[48],[63],{"name":64,"affiliation":5,"role":65},"Clinical Trials","STUDY_DIRECTOR",[67,72],{"name":68,"role":69,"phone":70,"phoneExt":11,"email":71},"Reference Study ID Number: BP46554 https:\u002F\u002Fforpatients.roche.com\u002F No attachments to email below.","CONTACT","888-662-6728","global-roche-genentech-trials@gene.com",{"name":73,"role":69,"phone":11,"phoneExt":11,"email":11},"Fastest response: use the inquiry form. https:\u002F\u002Fwww.gene.com\u002Fcontact-us\u002Fsubmit-medical-inquiry",{"type":75,"investigatorFullName":11,"investigatorTitle":11,"investigatorAffiliation":11,"oldNameTitle":11,"oldOrganization":11},"SPONSOR","100653104","phase-2-study-to-test-effects-and-safety-of-ro7568282-in-early-symptomatic-alzheimers-disease-100653104",false,"NCT07781657","Study to Test Effects and Safety of RO7568282 in Early Symptomatic Alzheimer's Disease","A Phase II, Randomized, Double-blind, Placebo-controlled, Multicenter Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of RO7568282 in Participants With Early Symptomatic Alzheimer's Disease","TARBELA-AD","Inclusion Criteria:\n\n* Evidence of AD pathological process, as confirmed by either amyloid positron emission tomography (PET) scan or cerebrospinal fluid (CSF)\n* Mild cognitive impairment (MCI) or mild dementia due to AD\n* Able to swallow whole capsules\n* Body mass index (BMI) within the range of 18-34 kilograms per square metre (kg\u002Fm²) (at screening)\n* Availability of an appropriate study partner\n\nExclusion Criteria:\n\n* Any evidence of a condition other than AD that may affect cognition\n* Participants must not have unstable or clinically significant cardiovascular disease within the last year, chronic uncontrolled hypertension, or clinically significant electrocardiogram (ECG) abnormalities\n* History or presence of clinically significant cerebrovascular disease\n* Clinically significant cerebral abnormalities on magnetic resonance imaging (MRI)\n\nNote: Other protocol-defined inclusion\u002Fexclusion criteria may apply.","ALL","50 Years","90 Years",{"count":88,"type":89},450,"ESTIMATED","INTERVENTIONAL",[92],"PHASE2","This study aims to compare the effects of RO7568282 versus a placebo in people in the early stages of Alzheimer's disease (AD).",[95],"Alzheimer's Disease","NOT_YET_RECRUITING","2026-08-20",{"date":99,"type":100},"2026-08-24","ACTUAL",{"date":102,"type":89},"2026-10-31",{"date":104,"type":89},"2029-11-01",{"name":5,"class":6}]